{"id":2336,"date":"2020-07-10T00:00:00","date_gmt":"2020-07-10T00:00:00","guid":{"rendered":"http:\/\/centogene.vl22350.dinaserver.com\/2336"},"modified":"2020-07-10T00:00:00","modified_gmt":"2020-07-10T00:00:00","slug":"a-centogene-anuncia-a-precificacao-de-sua-oferta-publica-primaria-e-secundaria-de-acoes-ordinarias","status":"publish","type":"post","link":"https:\/\/www.centogene.com\/pt\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/","title":{"rendered":"A CENTOGENE anuncia a defini\u00e7\u00e3o de pre\u00e7os para sua oferta p\u00fablica prim\u00e1ria e secund\u00e1ria de a\u00e7\u00f5es ordin\u00e1rias."},"content":{"rendered":"

CAMBRIDGE, Massachusetts, ROSTOCK, Alemanha e BERLIM, 9 de julho de 2020 (Globe Newswire) \u2013 A Centogene NV (Nasdaq: CNTG) (\u201cCentogene\u201d ou a \u201cEmpresa\u201d), uma empresa em fase comercial focada em doen\u00e7as raras que transforma dados cl\u00ednicos e gen\u00e9ticos do mundo real em informa\u00e7\u00f5es acion\u00e1veis para pacientes, m\u00e9dicos e empresas farmac\u00eauticas, anunciou hoje o pre\u00e7o de sua oferta p\u00fablica prim\u00e1ria e secund\u00e1ria de 3.500.000 a\u00e7\u00f5es ordin\u00e1rias da Empresa, consistindo em 2.000.000 a\u00e7\u00f5es ordin\u00e1rias oferecidas pela Empresa e 1.500.000 a\u00e7\u00f5es ordin\u00e1rias oferecidas por acionistas vendedores, ao pre\u00e7o de $14,00 por a\u00e7\u00e3o ordin\u00e1ria, totalizando uma receita bruta para a Empresa de $28 milh\u00f5es e uma receita bruta total para os acionistas vendedores de $21 milh\u00f5es. A Empresa n\u00e3o receber\u00e1 nenhuma receita da venda de a\u00e7\u00f5es ordin\u00e1rias pelos acionistas vendedores. Al\u00e9m disso, os acionistas vendedores concederam aos subscritores uma op\u00e7\u00e3o de 30 dias para adquirir at\u00e9 525.000 a\u00e7\u00f5es ordin\u00e1rias adicionais ao pre\u00e7o da oferta p\u00fablica, menos os descontos e comiss\u00f5es de subscri\u00e7\u00e3o.<\/p>\n

A conclus\u00e3o da oferta est\u00e1 prevista para 14 de julho de 2020 ou em data pr\u00f3xima, sujeita \u00e0s condi\u00e7\u00f5es habituais de fechamento.<\/p>\n

O Credit Suisse e o SVB Leerink atuam como coordenadores conjuntos da oferta, com o Baird, o BTIG e a Kempen & Co atuando como co-coordenadores.<\/p>\n

A Centogene pretende utilizar os recursos l\u00edquidos da oferta para pesquisa e desenvolvimento, visando apoiar o desenvolvimento de medicamentos \u00f3rf\u00e3os com sua plataforma de informa\u00e7\u00f5es baseada em conhecimento, bem como para capital de giro e outras finalidades corporativas gerais. Uma parte dos recursos l\u00edquidos tamb\u00e9m poder\u00e1 ser utilizada para adquirir ou investir em neg\u00f3cios, ativos ou tecnologias complementares.<\/p>\n

Uma declara\u00e7\u00e3o de registro relativa a esses t\u00edtulos foi declarada efetiva pela Comiss\u00e3o de Valores Mobili\u00e1rios dos EUA (\u201cSEC\u201d) em 9 de julho de 2020. A oferta est\u00e1 sendo feita somente por meio de um prospecto. C\u00f3pias do prospecto final relativo \u00e0 oferta podem ser obtidas, quando dispon\u00edveis, gratuitamente, visitando o EDGAR no site da SEC em www.sec.gov. Alternativamente, c\u00f3pias do prospecto final, quando dispon\u00edveis, podem ser obtidas junto \u00e0 Credit Suisse Securities (USA) LLC, aos cuidados do Departamento de Prospectos, 6933 Louis Stephens Drive, Morrisville, NC 27560, pelo telefone (800) 221-1037 ou pelo e-mail usa.prospectus@credit-suisse.com; ou junto \u00e0 SVB Leerink LLC, aos cuidados do Departamento de Sindicato, One Federal Street, 37\u00ba andar, Boston, MA 02110, pelo telefone (800) 808-7525, ramal 1037. 6218 ou por e-mail para syndicate@svbleerink.com.<\/p>\n

Este comunicado de imprensa n\u00e3o constitui uma oferta de venda ou uma solicita\u00e7\u00e3o de oferta de compra destes t\u00edtulos, nem haver\u00e1 qualquer venda destes t\u00edtulos em qualquer estado ou jurisdi\u00e7\u00e3o em que tal oferta, solicita\u00e7\u00e3o ou venda seja ilegal antes do registro ou qualifica\u00e7\u00e3o de acordo com as leis de valores mobili\u00e1rios de tal estado ou jurisdi\u00e7\u00e3o.<\/p>\n

\u201cNa CENTOGENE, orgulhamo-nos de fornecer aos nossos pacientes testes de diagn\u00f3stico em que podem confiar\u201d, acrescenta o Dr. Florian Vogel, Vice-Presidente S\u00e9nior de Opera\u00e7\u00f5es de Laborat\u00f3rio Cl\u00ednico. \u201cCom a nossa recente iniciativa de testes para a COVID-19, demonstr\u00e1mos que, mesmo em situa\u00e7\u00f5es de escassez de recursos, \u00e9 poss\u00edvel desenvolver e disponibilizar rapidamente testes de alta qualidade, em conformidade com as diretrizes da OMS\/CDC.\u201d.<\/p>\n

Sobre a CENTOGENE <\/strong><\/h2>\n

A CENTOGENE dedica-se ao diagn\u00f3stico e \u00e0 pesquisa de doen\u00e7as raras, transformando dados cl\u00ednicos e gen\u00e9ticos do mundo real em informa\u00e7\u00f5es pr\u00e1ticas para pacientes, m\u00e9dicos e empresas farmac\u00eauticas. Nosso objetivo \u00e9 trazer racionalidade \u00e0s decis\u00f5es de tratamento e acelerar o desenvolvimento de novos medicamentos \u00f3rf\u00e3os, utilizando nosso amplo conhecimento em doen\u00e7as raras, incluindo dados epidemiol\u00f3gicos e cl\u00ednicos, bem como biomarcadores inovadores. A CENTOGENE desenvolveu uma plataforma global propriet\u00e1ria para doen\u00e7as raras, baseada em nosso reposit\u00f3rio de dados do mundo real, com aproximadamente 3 bilh\u00f5es de pontos de dados ponderados de mais de 530.000 pacientes representando mais de 120 pa\u00edses diferentes, em 31 de mar\u00e7o de 2020.<\/p>\n

A plataforma da empresa inclui dados epidemiol\u00f3gicos, fenot\u00edpicos e gen\u00e9ticos que refletem uma popula\u00e7\u00e3o global, al\u00e9m de um biobanco de amostras de sangue desses pacientes. A CENTOGENE acredita que esta \u00e9 a \u00fanica plataforma capaz de analisar de forma abrangente dados em m\u00faltiplos n\u00edveis para aprimorar a compreens\u00e3o de doen\u00e7as heredit\u00e1rias raras, o que pode auxiliar na identifica\u00e7\u00e3o de pacientes e melhorar a capacidade de nossos parceiros farmac\u00eauticos de lan\u00e7ar medicamentos \u00f3rf\u00e3os no mercado. Em 31 de mar\u00e7o de 2020, a empresa colaborava com 39 parceiros farmac\u00eauticos, abrangendo mais de 45 doen\u00e7as raras diferentes.<\/p>\n

Contato:<\/h5>\n

CENTOGENE
Ben Legg
Comunica\u00e7\u00e3o Corporativa
press@centogene.com<\/a><\/p>\n

Contato com a m\u00eddia <\/strong>
Consultoria FTI
Bridie Lawlor
+1.917.929.5684
bridie.lawlor@fticonsulting.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 09, 2020 (Globe Newswire) \u2013 Centogene N.V. (Nasdaq: CNTG) (\u201cCentogene\u201d or the […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2336","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"\nCENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares | CENTOGENE<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.centogene.com\/pt\/a-centogene-anuncia-a-precificacao-de-sua-oferta-publica-primaria-e-secundaria-de-acoes-ordinarias\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares | CENTOGENE\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 09, 2020 (Globe Newswire) \u2013 Centogene N.V. (Nasdaq: CNTG) (\u201cCentogene\u201d or the […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.centogene.com\/pt\/a-centogene-anuncia-a-precificacao-de-sua-oferta-publica-primaria-e-secundaria-de-acoes-ordinarias\/\" \/>\n<meta property=\"og:site_name\" content=\"CENTOGENE\" \/>\n<meta property=\"article:published_time\" content=\"2020-07-10T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"740\" \/>\n\t<meta property=\"og:image:height\" content=\"416\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"admincg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"admincg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\\\/\"},\"author\":{\"name\":\"admincg\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\"},\"headline\":\"CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares\",\"datePublished\":\"2020-07-10T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\\\/\"},\"wordCount\":677,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\\\/\",\"name\":\"CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares | CENTOGENE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\"},\"datePublished\":\"2020-07-10T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.centogene.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"name\":\"CENTOGENE\",\"description\":\"Guiding Precision Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.centogene.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\",\"name\":\"CENTOGENE\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"contentUrl\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"width\":246,\"height\":246,\"caption\":\"CENTOGENE\"},\"image\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/centogene\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UClZxtN_laC1_ZtCdxkasdPQ\",\"https:\\\/\\\/www.instagram.com\\\/_centogene_\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\",\"name\":\"admincg\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/pt\\\/author\\\/admincg\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CENTOGENE anuncia o pre\u00e7o da oferta p\u00fablica prim\u00e1ria e secund\u00e1ria de a\u00e7\u00f5es ordin\u00e1rias | CENTOGENE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.centogene.com\/pt\/a-centogene-anuncia-a-precificacao-de-sua-oferta-publica-primaria-e-secundaria-de-acoes-ordinarias\/","og_locale":"pt_BR","og_type":"article","og_title":"CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares | CENTOGENE","og_description":"CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 09, 2020 (Globe Newswire) \u2013 Centogene N.V. (Nasdaq: CNTG) (\u201cCentogene\u201d or the […]","og_url":"https:\/\/www.centogene.com\/pt\/a-centogene-anuncia-a-precificacao-de-sua-oferta-publica-primaria-e-secundaria-de-acoes-ordinarias\/","og_site_name":"CENTOGENE","article_published_time":"2020-07-10T00:00:00+00:00","og_image":[{"width":740,"height":416,"url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp","type":"image\/webp"}],"author":"admincg","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"admincg","Est. tempo de leitura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.centogene.com\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/#article","isPartOf":{"@id":"https:\/\/www.centogene.com\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/"},"author":{"name":"admincg","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b"},"headline":"CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares","datePublished":"2020-07-10T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.centogene.com\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/"},"wordCount":677,"commentCount":0,"publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.centogene.com\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.centogene.com\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/","url":"https:\/\/www.centogene.com\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/","name":"CENTOGENE anuncia o pre\u00e7o da oferta p\u00fablica prim\u00e1ria e secund\u00e1ria de a\u00e7\u00f5es ordin\u00e1rias | CENTOGENE","isPartOf":{"@id":"https:\/\/www.centogene.com\/#website"},"datePublished":"2020-07-10T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.centogene.com\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.centogene.com\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.centogene.com\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.centogene.com\/"},{"@type":"ListItem","position":2,"name":"CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares"}]},{"@type":"WebSite","@id":"https:\/\/www.centogene.com\/#website","url":"https:\/\/www.centogene.com\/","name":"CENTOGENE","description":"Orientando a Medicina de Precis\u00e3o","publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.centogene.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/www.centogene.com\/#organization","name":"CENTOGENE","url":"https:\/\/www.centogene.com\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","contentUrl":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","width":246,"height":246,"caption":"CENTOGENE"},"image":{"@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/centogene","https:\/\/www.youtube.com\/channel\/UClZxtN_laC1_ZtCdxkasdPQ","https:\/\/www.instagram.com\/_centogene_\/"]},{"@type":"Person","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b","name":"admincg","url":"https:\/\/www.centogene.com\/pt\/author\/admincg\/"}]}},"_links":{"self":[{"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/posts\/2336","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/comments?post=2336"}],"version-history":[{"count":0,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/posts\/2336\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/media?parent=2336"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/categories?post=2336"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/tags?post=2336"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}